Breast & gyn med onc @valleyhealthnj. Opinions my own. Host of INTERLUDE podcast. 📗 BEYOND THE PINK (2026). Patient education on Instagram.
New Jersey, USA
Joined December 2017
- Tweets5.4K
- Following1.2K
- Followers4K
- Likes7.6K
Pinned Tweet
ONE MONTH to go until Beyond the Pink is out in the world!! Would love to see you on one of these book tour stops (and more to come). For info and registration links: drteplinsky.com/booktour.
Eleonora Teplinsky, MD, FASCO retweeted
How can you better advocate for yourself at the doctor? Dr. Eleonora Teplinsky shares three tips:
1Name your concern.
2Bring someone with you for support.
3Don’t be afraid to get a second opinion.
Head to our YouTube to watch the full story and continue the conversation with The Breasties’ Bri Majsiak and Trish Michelle, along with Dr. Eleonora Teplinsky.
#TamronHallShow #WomensHealth #CancerAwareness #HealthTips #BreastCancerAwareness
Eleonora Teplinsky, MD, FASCO retweeted
📣@drteplinsky #ascoqlty26 on strengthening pt/doctor trust in digital world.
- trust in MD/DOs ⬇️ 71% in 2020 to 49% in 2024
-educational digital use in pts ⬆️ 50 to 90% but only 9% report trust in data
-prebunk before you debunk tips ⬇️ Dr capella et al
@ASCO @JCOOP_ASCO
Eleonora Teplinsky, MD, FASCO retweeted
Tissue-Free vs Tumor-Informed Circulating Tumor DNA Assays in Early Triple Negative Breast Cancer jamanetwork.com/journals/jam…
Eleonora Teplinsky, MD, FASCO retweeted
Excellent presentation by @drteplinsky to kick off session on preserving trust as patients, #AI, & industry redefine the clinicians role-
How do we strengthen & preserve pt/clinician trust in a digital world?
Takeaways-
-digital literacy is needed
-give info prescription
Eleonora Teplinsky, MD, FASCO retweeted
“Trust is paramount in #CancerCare,” said 1st speaker @drteplinsky. How are AI, virtual peer networks & industry shifts redefining the pt-physician relationship? Join us now for Preserving Trust as Patients, AI & Industry Redefine the Clinician’s Role: bit.ly/4ART9OG
Physicians remain patients’ preferred source for vetting online content and data from an analysis on Reddit showed that medical mistrust was often driven by feeling dismissed, perceived lack of thoroughness and poor/inconsistent communication. Yet- all of these things take time and need education.
Dr @drteplinsky on how to "be the trusted voice" by addressing patient concerns, acknowledging their fears, and "prebunk" future interaction with #misinformation
#ASCOQLTY26
Thank you @JamesFanWu - clinicians are increasingly becoming ‘media educators’ but yet where is the education and support for them to do this? It will take more than an individual effort. #ASCOQLTY26
Dr. @drteplinsky from @valleyhealthnj kicking off the session and presenting on Beyond the Screen: Strengthening Patient/Clinician Trust in a Digital World. In patient canre and especially cancer care where trust is so essential, the modern digital age and even more so with AI, misinformation has become an even more of a challenge. In patients with cancer, 91% use smartphones and 54% use health apps. In this digital/AI age, do clinicians now need formal training and guidance on how to tackle the challenges on new sources of misinformation and debunk and prebunk? We often stress digitial literacy for our patients, but I think clinicans also need this as well. #ASCOQLTY26
@YAbdouMD @AndreaAnampaG @asfeen_ummul @crisbergerot @DarcyBurbage @ZunairahShah @RyanNipp @fumikochino @HannahRAbrams @ASCO
Eleonora Teplinsky, MD, FASCO retweeted
Dr @drteplinsky starting the #ASCOQLTY26 session on "Preserving Trust as Patients, Artificial Intelligence, & Industry Redefine the Clinician’s Role" speaking on OUR role on how to protect & build trust an an anchor of the therapeutic relationship in the era of #misinformation.
Eleonora Teplinsky, MD, FASCO retweeted
We join the oncology community in mourning the passing of Dr. Rachna T. Shroff, a renowned GI cancers expert and a dedicated ASCO volunteer. We are humbled by her dedication and strive to honor her legacy of commitment and altruism.
Read more: bit.ly/4e7jBKu
Eleonora Teplinsky, MD, FASCO retweeted
@rachnatshroff’s brilliant smile & signature sparkles lit up every room, but her devotion to @ASCO & biliary cancer research left an even brighter legacy. We are proud that her light will live on forever through an endowed @ConquerCancerFd YIA grant in her name. @ninashah33
Eleonora Teplinsky, MD, FASCO retweeted
Same Recurrence Score. Different underlying biology.
Our recent #RxPONDER analysis in @JNCI_Now found that gene pathway components (proliferation, ER, HER2) differed by race/ethnicity despite similar overall recurrence scores.
Could looking inside the score help us understand outcome disparities?
@KalinskyKevin @UNC_Lineberger @WinshipAtEmory @SWOG
doi.org/10.1093/jnci/djag221 academic.oup.com/jnci/articl…
It’s 10 days until publication day for 📗 Beyond The Pink and I am counting down with the 🔟 things I wish everyone knew about #breastcancer.
Eleonora Teplinsky, MD, FASCO retweeted
⭐️ How are #BreastCancer experts using #ctDNA in real-world practice?
@MatthewKurianMD @mchayleh @drteplinsky @OncBrothers 🗣️
🔹Detecting recurrence earlier
🔸Limitations
🔹Shared decision-making
🔸Future role of ctDNA in breast cancer care #bcsm
🎥👇
oncupdates.com/video-podcast…
Eleonora Teplinsky, MD, FASCO retweeted
FDA grants accelerated approval to Etcamah (camizestrant) + CDK4/6i (abemaciclib, palbociclib, ribociclib) for HR+/HER2- advanced BC upon ESR1 mutation detected during AI + CDK4/6i therapy, by FDA-authorized test.
Pro: mPFS 16 vs 9.2 mo per label. In SERENA-6, final PFS2 25.7 vs 19.1 mo (HR 0.63) and 46% lower risk of deterioration in global health status/QOL.
Con: Accelerated approval, OS immature, confirmatory trials required. Boxed warning for irregular heart rhythm with certain concomitant meds, plus bradycardia.
First trial to intervene on molecular resistance in breast cancer before clinical PD.
#bcsm
After #ASCO25 Plenary, Camizestrant is now @US_FDA ✅ based off #SERENA6: PhIII, Camizestrant + CDK4/6i vs AI + CDK4/6i for emerging ESR1m before progression.
- mPFS2: 25.7mos vs. 19.1mos (HR: 0.63)
- mPFS: 16.8mos vs. 9.2mos (HR: 0.45)
#OncTwitter #bcsm #MedX @OncoAlert
Eleonora Teplinsky, MD, FASCO retweeted
In a new NEJM Voices blog post, Don Dizon, MD, reflects on the profound shock of a colleague’s cancer diagnosis. Read “When Cancer Hits Home” and sign up for email alerts: nej.md/4i0fMK1
ALT A photo from the NEJM Voices blog post "When Cancer Hits Home" by Don Dizon, M.D. In the photo, Dr. Dizon and Dr. Rachna Shroff sit in front of a sign that reads, "The Women in Oncology Awards." Dr. Shroff is wearing a lei (the photo was taken in Hawaii).
Eleonora Teplinsky, MD, FASCO retweeted
Rest in Power @ASCO Giant Dr Harold Paul Freeman 1933-2026
Your work outlining barriers to care and developing #patientNavigation has saved countless lives & was foundational to a generation of researchers like me.
connection.asco.org/do/asco-…
Eleonora Teplinsky, MD, FASCO retweeted
It was lovely to speak with Eleonora Teplinsky (@drteplinsky) at #ASCO26 to discuss the importance of educating patients about the potential risks of using #AI for health information🖥️
Misinformation and "hallucination" by AI systems can create potential conflicts between clinician recommendations and impact patient outcomes 📉
Watch: ow.ly/rhCe50ZHLWU
#Oncology @ASCO @ValleyHealthNJ
Eleonora Teplinsky, MD, FASCO retweeted
Not every patient needs an aromatase inhibitor. Eleonora Teplinsky, MD, FASCO, tells Sara Nunnery, MD, MSCI, why lowering recurrence risk in breast cancer must be individualized, not one-size-fits-all.
🎙️Watch the full episode of Breast Cancer Briefing on OncLive®: hubs.ly/Q04txPGV0
@SaraNunneryMD @drteplinsky #BreastCancerBriefing #RecurrenceRisk #PrecisionOncology #BreastCancer #OncLive
Eleonora Teplinsky, MD, FASCO retweeted
Dolly Parton is reported to have died from cancer. A reminder that cancer affects everyone.
people.com/dolly-parton-died…
